We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Illumina (ILMN - Free Report) is a life sciences company that offers tools and integrated systems for genetic variation analysis. The company also provides innovative sequencing- and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA.
Q2 Earnings Disappoint Wall Street
Illumina reported second quarter financial numbers last month, and results fell short of expectations. ILMN dropped as much as 13% the day of its earnings release.
Revenue of $633 million declined 25% year-over-year, though this is what analysts had been anticipating. Non-GAAP earnings were $0.62 per share, missing analysts’ expectations.
R&D expenses were $155 million for the quarter.
Cash flow from operations, however, improved over the prior-year period to $240 million; free cash flow was $202 million, also improving year-over-year.
"As expected, the second quarter was significantly impacted by pandemic-related disruption in our customers' operations and was particularly challenging for many of our research customers who remain closed or operating at limited scale,” said CEO Francis deSouza.
ILMN withdrew its full-year fiscal 2020 guidance earlier this year, and uncertainty around the coronavirus pandemic still remains.
Bottom Line
ILMN is now a Zacks Rank #5 (Strong Sell).
Seven analysts cut their full year earnings outlook over the past 60 days, and the consensus estimate has fallen well over one dollar to $4.39 per share; earnings are expected to decline about 33% for fiscal 2020.
Shares have actually gained more than 44% since the March lows, but ILMN still lags the S&P 500’s 55+% rebound during the same time frame.
ILMN will likely have a long, hard road ahead of it, since the Covid-19 crisis will continue to be a growth obstacle for a while now. But, the broader genome sequencing market has huge growth opportunities, and Illumina could be poised for a big rebound once the pandemic subsides.
Investors who are interested in adding a medical peer to their portfolio could consider scientific instrument maker Thermo Fisher Scientific (TMO - Free Report) . TMO is a #2 (Buy) on the Zacks Rank, and shares have jumped almost 58% since mid-March.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Bear of the Day: Illumina (ILMN)
Illumina (ILMN - Free Report) is a life sciences company that offers tools and integrated systems for genetic variation analysis. The company also provides innovative sequencing- and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA.
Q2 Earnings Disappoint Wall Street
Illumina reported second quarter financial numbers last month, and results fell short of expectations. ILMN dropped as much as 13% the day of its earnings release.
Revenue of $633 million declined 25% year-over-year, though this is what analysts had been anticipating. Non-GAAP earnings were $0.62 per share, missing analysts’ expectations.
R&D expenses were $155 million for the quarter.
Cash flow from operations, however, improved over the prior-year period to $240 million; free cash flow was $202 million, also improving year-over-year.
"As expected, the second quarter was significantly impacted by pandemic-related disruption in our customers' operations and was particularly challenging for many of our research customers who remain closed or operating at limited scale,” said CEO Francis deSouza.
ILMN withdrew its full-year fiscal 2020 guidance earlier this year, and uncertainty around the coronavirus pandemic still remains.
Bottom Line
ILMN is now a Zacks Rank #5 (Strong Sell).
Seven analysts cut their full year earnings outlook over the past 60 days, and the consensus estimate has fallen well over one dollar to $4.39 per share; earnings are expected to decline about 33% for fiscal 2020.
Shares have actually gained more than 44% since the March lows, but ILMN still lags the S&P 500’s 55+% rebound during the same time frame.
ILMN will likely have a long, hard road ahead of it, since the Covid-19 crisis will continue to be a growth obstacle for a while now. But, the broader genome sequencing market has huge growth opportunities, and Illumina could be poised for a big rebound once the pandemic subsides.
Investors who are interested in adding a medical peer to their portfolio could consider scientific instrument maker Thermo Fisher Scientific (TMO - Free Report) . TMO is a #2 (Buy) on the Zacks Rank, and shares have jumped almost 58% since mid-March.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>